Novartis wraps up acquisition of Takeda’s dry eye drug Xiidra

This article was originally published here

The sale of Xiidra has also provided an option to Takeda to receive up to an additional $1.9bn (£1.5bn) in potential milestone payments from Novartis. Takeda intends to

The post Novartis wraps up acquisition of Takeda’s dry eye drug Xiidra appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply